

























![]()
Q1: 2026-05-12 Earnings Summary
EPS of -$0.83 misses by $0.05
|
Revenue of
$18.27M
(29.47% Y/Y)
misses by $7.65M
Kura Oncology, Inc. (KURA) Q1 2026 Earnings Call May 12, 2026 4:30 PM EDT
Company Participants
Greg Mann - Senior Vice President of Investor Relations & Corporate Affairs
Troy Wilson - Chairman, CEO & President
Brian Powl - Chief Commercial Officer
Mollie Leoni - Chief Medical Officer
Thomas Doyle - Senior Vice President of Finance & Accounting
Conference Call Participants
Daniel Bronder - Cantor Fitzgerald & Co., Research Division
Peter Green - LifeSci Capital, LLC, Research Division
Jonathan Chang - Leerink Partners LLC, Research Division
Etzer Darout - Barclays Bank PLC, Research Division
Reni Benjamin - Citizens JMP Securities, LLC, Research Division
Nabeel Nissar - Jefferies LLC, Research Division
Philip Nadeau - TD Cowen, Research Division
Salim Syed - Mizuho Securities USA LLC, Research Division
Xiaochuan Dai - UBS Investment Bank, Research Division
Daniel Brims - Lake Street Capital Markets, LLC, Research Division
Presentation
Operator
Good day, everyone. My name is Leila, and I will be your conference operator today. At this time, I would like to welcome you to the Kura Oncology First Quarter 2026 Financial Results Earnings Call. [Operator Instructions]
At this time, I would like to turn the call over to Greg Mann, SVP of Investor Relations and Corporate Affairs of Kura Oncology. Please go ahead.
Greg Mann
Senior Vice President of Investor Relations & Corporate Affairs
Thank you, Leila. Good afternoon, and welcome to Kura Oncology's First Quarter 2026 Conference Call. Joining the call today are Dr. Troy Wilson, President and Chief Executive Officer; Brian Powl, Chief Commercial Officer; Dr. Mollie Leoni, Chief Medical Officer; and Tom Doyle, Senior Vice President, Finance and Accounting.
We remind you that today's discussion will include forward-looking statements based on current expectations. Such statements represent management's judgment as of today and may involve risks and uncertainties that cause actual results to differ materially from expected results. Please refer to Kura's filings with the
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。